A systematic review and meta-analysis indicate that neoadjuvant chemotherapy (nCTX) does not offer survival benefits for esophagogastric signet ring cell carcinoma (SRCC) patients. The meta-analysis, which included 3,653 patients from 10 studies, revealed that SRCC patients treated with nCTX followed by surgery have worse survival outcomes compared to those treated with surgery alone. Additionally, SRCC patients exhibit lower histopathological response rates to nCTX compared to non-SRCC patients. These findings highlight the need for further high-quality research to determine the most effective treatment strategies for SRCC. #GastricCancer #NeoadjuvantChemotherapy #OncologyResearch #SurgicalOncology
Get health updates from Dr Harsh Shah on WhatsApp
Swasth Parivar: twice a month, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.